Long-acting injectable HIV therapy versus daily orals - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-acting injectable HIV therapy versus daily orals

  • By

  • Matthew Solan

  • November 5, 2026

  • 3 min

Share

  • 1

    The observational OPERA analysis included 7,995 adults who switched from oral antiretroviral therapy to injectable cabotegravir plus rilpivirine during 2021–2025. At initiation, 6,955 (87%) had viral loads below 50 copies/mL.

  • 2

    Among 6,362 initially suppressed patients who completed initiation, 77% remained in care and on injectable therapy at study end, with or without interruptions. Initiation required the first two injections no more than 67 days apart.

  • 3

    During these patients’ first uninterrupted treatment course, 94% had a viral load below 50 copies/mL at their last measurement, while 81% were below that threshold at every measurement.

  • 4

    Confirmed virologic failure occurred in 1%. According to Dr. Ricky Hsu, 95% received injections on time or had only one late injection within 5 days of the recommended window.

  • 5

    Among 182 surveys of provider-confirmed discontinuations, representing 10% of discontinuations, the leading reported reasons were nonadherence to injection visits (29%), loss to care (23%) and a desire to switch to oral therapy (15%).

Original Source(s)

Related Content